Royal Bank Of Canada Reaffirms “Sector Perform” Rating for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “sector perform” rating restated by Royal Bank Of Canada in a research report issued to clients and investors on Tuesday, Benzinga reports. They presently have a $737.00 price objective on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target would suggest a potential downside of 2.03% from the stock’s previous close.

A number of other research firms also recently commented on REGN. Guggenheim raised their target price on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Sanford C. Bernstein upgraded shares of Regeneron Pharmaceuticals to a “hold” rating in a research note on Wednesday, July 29th. Benchmark raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective on the stock in a report on Tuesday, July 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday, September 21st. Finally, Wells Fargo & Company upped their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. Fourteen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $802.18.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $752.25 on Tuesday. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The business’s 50 day moving average is $781.41 and its two-hundred day moving average is $720.99. Regeneron Pharmaceuticals has a 12-month low of $541.00 and a 12-month high of $859.34. The stock has a market capitalization of $77.45 billion, a price-to-earnings ratio of 18.59, a PEG ratio of 1.54 and a beta of 0.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. During the same period last year, the firm earned $12.81 EPS. The company’s quarterly revenue was up 16.7% compared to the same quarter last year. Research analysts expect that Regeneron Pharmaceuticals will post 44.25 EPS for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the completion of the transaction, the director owned 603 shares of the company’s stock, valued at approximately $512,550. This trade represents a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 4,146 shares of company stock valued at $3,432,488. Company insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. SHP Wealth Management purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $26,000. Western Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals during the first quarter worth approximately $26,000. Titan Wealth CI Ltd acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $29,000. Mowery & Schoenfeld Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $29,000. Finally, Trust Co. of Vermont acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at $29,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.